Kynurenine Metabolites and Migraine: Experimental Studies and Therapeutic Perspectives

Author(s): Annamaria Fejes, Arpad Pardutz, Jozsef Toldi, Laszlo Vecsei.

Journal Name: Current Neuropharmacology

Volume 9 , Issue 2 , 2011

Become EABM
Become Reviewer

Abstract:

Migraine is one of the commonest neurological disorders. Despite intensive research, its exact pathomechanism is still not fully understood and effective therapy is not always available. One of the key molecules involved in migraine is glutamate, whose receptors are found on the first-, second- and third-order trigeminal neurones and are also present in the migraine generators, including the dorsal raphe nucleus, nucleus raphe magnus, locus coeruleus and periaqueductal grey matter. Glutamate receptors are important in cortical spreading depression, which may be the electrophysiological correlate of migraine aura. The kynurenine metabolites, endogenous tryptophan metabolites, include kynurenic acid (KYNA), which exerts a blocking effect on ionotropic glutamate and α7-nicotinic acetylcholine receptors. Thus, KYNA and its derivatives may act as modulators at various levels of the pathomechanism of migraine. They can give rise to antinociceptive effects at the periphery, in the trigeminal nucleus caudalis, and may also act on migraine generators and cortical spreading depression. The experimental data suggest that KYNA or its derivatives might offer a novel approach to migraine therapy.

Keywords: Cortical spreading depression, glutamate, kynurenic acid, kynurenine metabolites, migraine, migraine generators, trigeminal system, neurological disorders, trigeminal ganglion (TG), inflammation-inducedhyperalgesia

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 9
ISSUE: 2
Year: 2011
Page: [376 - 387]
Pages: 12
DOI: 10.2174/157015911795596621
Price: $58

Article Metrics

PDF: 1